The FDA has accepted ImmunityBio's supplemental Biologics License Application (sBLA) for ANKTIVA to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This acceptance marks a key advancement for the company, with a PDUFA action date set for January 6, 2027. The application is backed by positive Phase 2/3 trial data showing a 58.2% 12-month disease-free survival rate. ImmunityBio's stock rose over 8% in premarket trading following the news, reflecting strong investor confidence in the drug's potential.
Holzer & Holzer, LLC announced approaching deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Vital Farms, Super Micro Computer, and Aldeyra Therapeutics. These lawsuits allege misleading statements or ...
Lifestyle expert Meaghan B. Murphy shares easy Memorial Day hosting tips featuring Wendy's upgraded Spicy Chicken Sandwich with a juicier marinade and bold spices, and a healthy Mediterranean Tuna Salad using Genova Premium Tuna. These food ideas com...
Holzer & Holzer, LLC announced upcoming deadlines for investors to apply as lead plaintiffs in shareholder class action lawsuits against Regencell Bioscience Holdings, SES AI Corporation, and POET Technologies. These lawsuits allege that the companie...
Keysight Technologies reported Q2 earnings of $2.87 per share, surpassing analyst estimates of $2.32, with revenue up 31% year-over-year to $1.72 billion. The company saw a 56% increase in orders, driven by strong demand in AI-related businesses, sem...
Red Cat Holdings has acquired Quaze Technologies, a company specializing in wireless power transfer for unmanned systems. This acquisition addresses a key challenge in robotic autonomy by enabling autonomous recharging without manual battery swaps or...
